Novozymes A/S
NVZMY | OTC
$69.17
+$0.11 (+0.15%)
Nov 2, 2026, 3:42 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 4.15B | 3.83B | 17.9B | 2.36B | 2.01B | 14.01B |
Cost of Revenue | 1.91B | 2.02B | 8.18B | 1.07B | 850.85M | 6.16B |
Gross Profit | 2.24B | 1.81B | 9.72B | 1.29B | 1.16B | 7.85B |
Operating Income | 881.93M | 658.48M | 4.55B | 621.27M | 538.77M | 3.65B |
Interest Income | 20.97M | 26.88M | 90M | 18M | 18M | 10M |
Pretax Income | 742.84M | 416.77M | 3.91B | 611.47M | 527.61M | 3.52B |
Net Income | 583.16M | 305.56M | 3.02B | 493.36M | 423M | 2.83B |
Selling & General & Admin | 911.11M | 764.9M | 3.32B | 432.56M | 375.81M | 2.32B |
Research & Development | 463.45M | 412.88M | 2.02B | 268.56M | 270.13M | 1.94B |
Other Expenses | -16.69M | -28.18M | -170.62M | -37.04M | -25.28M | -56M |
Operating Expenses | 1.36B | 1.15B | 5.17B | 664.08M | 620.66M | 4.2B |
Interest Expense | 80.47M | 87.55M | 223M | 158M | 72M | 94M |
Selling & Marketing Expenses | 688.08M | 550.47M | 2.36B | 304.79M | 260.31M | 1.58B |
Cost & Expenses | 3.27B | 3.17B | 13.35B | 1.73B | 1.47B | 10.36B |
Income Tax Expense | 159.68M | 111.21M | 870.25M | 116.76M | 104.74M | 695M |
Shares Outstanding (Basic) | 414.56M | 457.62M | 277.04M | 276.64M | 277.92M | 280.43M |
Shares Outstanding (Diluted) | 466.88M | 459.61M | 277.87M | 278.73M | 280.23M | 282.02M |
EPS (Basic) | 1.25 | 0.67 | 10.95 | 1.78 | 1.52 | 10.07 |
EPS (Diluted) | 1.25 | 0.67 | 10.88 | 1.77 | 1.51 | 10.02 |
EBITDA | 1.39B | 1.04B | 5.47B | 820.71M | 1.92B | 4.85B |
EBIT | 811.09M | 493.11M | 4.08B | 625.16M | 541.33M | 3.58B |
Depreciation & Amortization | 574.36M | 543.67M | 1.39B | 195.55M | 1.37B | 1.27B |
Add to Watchlist
Select watchlists to add or remove NVZMY